Navigation Links
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
Date:7/2/2009

y company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase I/II REOLYSIN paclitaxel and carboplatin trial and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
2. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
3. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
4. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
5. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
7. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
8. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
9. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
10. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
11. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... The 20 ambassadors representing the ALS ... issued the following statement on Facebook today regarding the ... new funding specifically for ALS research: , “Who would ... ice would raise all this awareness and funding toward ... on behalf of the entire ALS community, would like ...
(Date:8/26/2014)... Israel , August 26, 2014 ... supports NHS hospitals with surgery validation using its Stratasys Objet24 ... - Performing surgery on 3D printed models prior to operations ... provides an effective aid for both patient and surgeon ... SSYS ), a global leader of 3D printing and additive ...
(Date:8/26/2014)... 2014   Lycera Corp ., a biopharmaceutical ... to treat autoimmune disease and cancer based on ... appointment of Harinder Singh , Ph.D., as ... Singh will lead the board,s efforts to provide ... research programs and pipeline of therapies targeting unmet ...
(Date:8/26/2014)... Vycom announced today that Modutek ... chemical process equipment, has selected its Flametec materials for ... Rare Isotope Beams (FRIB). This involved the creation ... with Vycom’s Flametec PVC-C and Kytec PVDF material to ... of FRIB’s linear accelerator (known as LINAC). ...
Breaking Biology Technology:ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3
... is First Entry to Home-Based Device Market Featuring Diode Laser ... ... SpectraGenics, a leader in,light-based therapeutic beauty devices, today announced ... (FDA),for their patented hand-held laser hair removal device designed for ...
... Live on Company,s Website -, TUSTIN, Calif., Feb. ... clinical stage biopharmaceutical,company developing monoclonal antibodies for the treatment ... senior management will,present at the 10th Annual BIO CEO ... am EST. The conference will be held at the,Waldorf-Astoria ...
... or "the Company") (OTC: BPYT) today announced that sales,for ... sales for the month,of January 2007., "We achieved ... continued success of our Flight Spray product. We are ... all-natural solution for,baby care marketed under the Gentle Mother(TM) ...
Cached Biology Technology:TRIA At-Home Laser Hair Removal Device Cleared by FDA 2Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January 2
(Date:8/27/2014)... news release is available in German . ... 1A is the most common inherited disease affecting the ... at the Max Planck Institute of Experimental Medicine and ... of Schwann cells is impaired in rats with the ... insulating layer known as myelin, which facilitates the rapid ...
(Date:8/27/2014)... lost or abandoned each year in U.S. waters and ... to catch fish, crabs, and other species such as ... and the watermen who depend on the resources--losses that ... study. , The report, published in the Marine ... to examine the derelict fish trap problem, and so-called ...
(Date:8/27/2014)... of seven hours ago the Happy Camp Complex of ... California, the July complex had consumed 35,530 as of ... fires on the Happy Camp Ranger District of the ... area on August 11, 2014. All but three of ... is a list of contained fires and their size ...
Breaking Biology News(10 mins):Potential therapy for incurable Charcot-Marie-Tooth disease 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2Happy Camp and July Fire Complexes in California 2
... as kudzu, privet and garlic mustard can devastate ecosystems, ... that native plants could mount a successful defense. ... native clearweed plants have evolved resistance to invasive garlic ... waging a counterattack. The study, published in the early ...
... Researchers at the Hollings Marine Laboratory (HML) and four ... of 13 perfluoroalkyl compounds (PFCs) in five different endangered ... not yet been conducted on turtles, the levels of ... amounts known to cause adverse health effects in other ...
... previously frozen ovarian tissue back into female cancer survivors can ... to a new study by Samuel Kim from the University ... shows that hormonal function was restored in five women 12-20 ... than seven years, appears online in the Journal of ...
Cached Biology News:Study provides first evidence of coevolution between invasive, native species 2Study provides first evidence of coevolution between invasive, native species 3Pollutants could pose health risks for 5 sea turtle species 2Pollutants could pose health risks for 5 sea turtle species 3Life span of ovarian grafts longer than expected 2
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 10 ... tubes. Box dimensions: 13 x 13 x ...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
Biology Products: